Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

82.73 UNCHANGED
Streaming Delayed Price Updated: 1:00 PM EST, Nov 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Ionis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
From Biogen Inc.
Via GlobeNewswire
News headline image
Biogen Completes Acquisition of Alcyone Therapeutics
From Biogen Inc.
Via GlobeNewswire
News headline image
DAWNZERA™ (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE)
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis Prices Convertible Notes Offering to Refinance 2026 Convertible Notes
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis to present at upcoming investor conferences
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis Announces Proposed Convertible Offering to Refinance 2026 Convertible Notes
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Groundbreaking pivotal study results of olezarsen for severe hypertriglyceridemia (sHTG) presented as a late breaker at AHA Scientific Sessions
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis presents new data demonstrating long-term disease control with DAWNZERA™ (donidalorsen) at ACAAI 2025 Annual Meeting
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis reports third quarter 2025 financial results and highlights progress on key programs
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Detailed data from the landmark CORE and CORE2 pivotal studies of olezarsen for sHTG to be presented as a late breaker at AHA Scientific Sessions
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis ranked #2 Top Employer by Science magazine, recognizing industry-leading scientific innovation and company culture
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis CEO Brett P. Monia receives 2025 Lifetime Achievement Award from the Oligonucleotide Therapeutics Society
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis to hold third quarter 2025 financial results webcast
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis showcases transformational medicines and industry-leading pipeline at Innovation Day
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen
From Biogen Inc.
Via GlobeNewswire
News headline image
Ionis announces positive topline results from pivotal study of zilganersen in Alexander disease
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
TRYNGOLZA® (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS)
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates
From Biogen Inc.
Via GlobeNewswire
News headline image
Ionis expands Surf Away+ event, marking 10 years of creating unique adaptive experiences for people with neurological diseases
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis receives U.S. FDA Breakthrough Therapy designation for ION582 in Angelman syndrome
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis to host investors and analysts for Innovation Day 2025
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis to present at upcoming investor conferences
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Olezarsen significantly reduces triglycerides and acute pancreatitis events in landmark pivotal studies for people with severe hypertriglyceridemia (sHTG)
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
DAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis reports second quarter 2025 financial results and highlights progress on key programs
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for familial chylomicronemia syndrome (FCS)
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Phase 3 OASISplus data demonstrating benefit of donidalorsen for HAE patients who switched from other prophylactics published in JACI In Practice
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis to hold second quarter 2025 financial results webcast
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA
From Biogen Inc.
Via GlobeNewswire
News headline image
Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results
From Ionis Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.